Journal article

Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer

Chi Gao, Chirag J Patel, Kyriaki Michailidou, Ulrike Peters, Jian Gong, Joellen Schildkraut, Fredrick R Schumacher, Wei Zheng, Paolo Boffetta, Isabelle Stucker, Walter Willett, Stephen Gruber, Douglas F Easton, David J Hunter, Thomas A Sellers, Christopher Haiman, Brian E Henderson, Rayjean J Hung, Christopher Amos, Brandon L Pierce Show all

International Journal of Epidemiology | OXFORD UNIV PRESS | Published : 2016

Grants

Awarded by Genetic Associations and Mechanisms in Oncology Network, GAME-ON


Awarded by Discovery, Biology, and Risk of Inherited Variants in Breast Cancer, DRIVE


Awarded by Elucidating Loci Involved in Prostate Cancer Susceptibility, ELLIPSE


Awarded by Follow-up of Ovarian Cancer genetic association and Interaction studies, FOCI


Awarded by Transdisciplinary Research in Cancer of the Lung, TRICL


Awarded by Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation


Awarded by Cancer Research UK


Awarded by National Institutes of Health


Awarded by Wellcome Trust


Awarded by Netherlands Organisation of Scientific Research NWO Investments


Awarded by Research Institute for Diseases in the Elderly


Awarded by Netherlands Consortium for Healthy Aging (NCHA)


Awarded by Genetic Associations and Mechanisms in Oncology (GAME-ON)


Awarded by National Cancer Institute


Funding Acknowledgements

This work was supported by the Genetic Associations and Mechanisms in Oncology Network, GAME-ON [http://epi.grants.cancer.gov/gameon/], which includes the following consortia: Colorectal Transdisciplinary Study, CORECT, PI: S. Gruber (grant number U19 CA148107); Discovery, Biology, and Risk of Inherited Variants in Breast Cancer, DRIVE, PI: D. Hunter (U19 CA148065); Elucidating Loci Involved in Prostate Cancer Susceptibility, ELLIPSE, PI: B. Henderson (grant number U19 CA148537); Follow-up of Ovarian Cancer genetic association and Interaction studies, FOCI, PI: T. Sellers (U19 CA148112); Transdisciplinary Research in Cancer of the Lung, TRICL, PI: C. Amos (U19 CA148127). This work was also supported by Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation (NIEHS K99ES023504, NIEHS R21 ES025052); Cancer Research UK (C1287/A16563); and National Institutes of Health (CA173785 and CA165131).We also acknowledge the following funding sources for breast cancer genome-wide association studies: BBCS: this work was funded by Cancer Research UK (C150/A5660, C1178/A3947); Breakthrough Breast Cancer; and the Institut National de Cancer.We acknowledge National Health Service funding to the NIHR Biomedical Research Centre and the National Cancer Research Network (NCRN). Funding for the project was provided by the Wellcome Trust (076113, 085475). Controls from the Dutch Familial Bilateral Breast Cancer Study (DFBBCS) are drawn from the Rotterdam Study: Rotterdam Study is supported by: the Netherlands Organisation of Scientific Research NWO Investments (no. 175.010.2005.011, 911-03-012); the Genetic Laboratory of the Department of Internal Medicine; Erasmus MC; the Research Institute for Diseases in the Elderly (014-93-015; RIDE2); the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO); Netherlands Consortium for Healthy Aging (NCHA)(no. 050-060-810); Erasmus Medical Center and Erasmus University, Rotterdam; Netherlands Organization for the Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science; the Ministry for Health, Welfare and Sports; the European Commission (DGx II); and the Municipality of Rotterdam.We also acknowledge the following funding sources for the Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI): the National Cancer Institute's Cancer Post-GWAS Initiative; Genetic Associations and Mechanisms in Oncology (GAME-ON) (U19-CA148112), (R01-CA114343, R01-CA114343-S1); National Cancer Institute (P30-CA15083); Cancer Research UK (C490/A8339); and the Wellcome Trust (076113).